These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21400979)

  • 21. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
    Bachow SH; Lamanna N
    Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
    Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
    Michallet AS; Cazin B; Bouvet E; Oberic L; Schlaifer D; Mosser L; Salles G; Coiffier B; Laurent G; Ysebaert L
    J Geriatr Oncol; 2013 Apr; 4(2):141-7. PubMed ID: 24071539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ofatumumab in the treatment of chronic lymphocytic leukemia.
    Tsimberidou AM
    Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chronic lymphocytic leukemia: current standards and novel approaches].
    Tausch E; Stilgenbauer S
    Internist (Berl); 2014 Dec; 55(12):1400, 1402-4, 1406-9. PubMed ID: 25392275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly.
    Goede V; Hallek M
    Drugs Aging; 2011 Mar; 28(3):163-76. PubMed ID: 21329399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C; Pitt M; Moxham T; Stein K
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic Options for "Slow go" Patients with Chronic Lymphocytic Leukemia].
    Smolej L
    Klin Onkol; 2015; 28 Suppl 3():3S30-8. PubMed ID: 26489499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of relapsed or refractory chronic lymphocytic leukemia.
    Veliz M; Pinilla-Ibarz J
    Cancer Control; 2012 Jan; 19(1):37-53. PubMed ID: 22143061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in chemotherapy for chronic lymphocytic leukemia.
    Wendtner CM; Eichhorst BF; Hallek MJ
    Semin Hematol; 2004 Jul; 41(3):224-33. PubMed ID: 15269882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
    Joffe E; Goldschmidt N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Arad A; Polliack A; Herishanu Y;
    Eur J Haematol; 2018 Sep; 101(3):399-406. PubMed ID: 29949186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
    Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
    Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How I treat patients with relapsed chronic lymphocytic leukaemia.
    Cuthill K; Devereux S
    Br J Haematol; 2013 Nov; 163(4):423-35. PubMed ID: 23992101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD
    Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
    Voorhies BN; Stephens DM
    Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.